Exparel Drug Insight and Market Forecast – 2032

Exparel Drug Insight and Market Forecast – 2032

“Exparel Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Exparel for Postoperative Pain in the 7MM. A detailed picture of the Exparel for Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Exparel for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Exparel market forecast, analysis for Postoperative Pain in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Postoperative Pain.

Drug Summary

Exparel (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired period. Exparel represents the multivesicular liposome local anesthetic that can be utilized in the peri-or postsurgical setting. By utilizing the DepoFoam platform, a single dose of Exparel delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78% decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated.

Exparel was approved by the FDA in October 2011 and was commercially launched in April 2012. Exparel is currently indicated for single-dose infiltration in adults to produce postsurgical local analgesia and an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. The company is planning to launch Exparel in targeted European countries beginning in the second half of 2021.

Exparel is available as a 266 mg/20 mL single-use vial and a 133 mg/10 mL single-use vial. The recommended dose of EXPAREL is based on (i) the size of the surgical site; (ii) the volume needed to cover the width and depth of the surgical site, and (iii) patient-specific factors that could impact the safety of an amide-type local anesthetic. The maximum dose should not exceed 266 mg.

Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rising of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of a loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Exparel description, mechanism of action, dosage and administration, research and development activities in Postoperative Pain.

Elaborated details on Exparel regulatory milestones and other development activities have been provided in this report.

The report also highlights the Exparel research and development activity in Postoperative Pain details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Exparel.

The report contains forecasted sales of Exparel for Postoperative Pain till 2032.

Comprehensive coverage of the late-stage emerging therapies for Postoperative Pain.

The report also features the SWOT analysis with analyst views for Exparel in Postoperative Pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Exparel Analytical Perspective by DelveInsight

In-depth Exparel Market Assessment

This report provides a detailed market assessment of Exparel in Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

Exparel Clinical Assessment

The report provides the clinical trials information of Exparel for Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Postoperative Pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Exparel dominance.

Other emerging products for Postoperative Pain are expected to give tough market competition to Exparel and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Exparel in Postoperative Pain.

Our in-depth analysis of the forecasted sales data of Exparel from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Exparel in Postoperative Pain.

Key Questions

What is the product type, route of administration and mechanism of action of Exparel?

What is the clinical trial status of the study related to Exparel in Postoperative Pain and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Exparel development?

What are the key designations that have been granted to Exparel for Postoperative Pain?

What is the forecasted market scenario of Exparel for Postoperative Pain?

What are the forecasted sales of Exparel in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Postoperative Pain and how are they giving competition to Exparel for Postoperative Pain?

Which are the late-stage emerging therapies under development for the treatment of Postoperative Pain?